CD4+ T-cell-mediated anti-tumor immunity can be uncoupled from autoimmunity via the STAT4/STAT6 signaling axis

European Journal of Immunology

Volumn 39, Issue 5, 2009, Pages 1252-1259

  Zhang, Sheng ^a   Bernard, Dannie ^a   Khan, Waliul I ^a   Kaplan, Mark H ^b   Bramson, Jonathan L ^a   Wan, Yonghong ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti tumor immunity; Autoimmunity; CD4+ T cells; Cytokines; Vaccination

Indexed keywords

ADENOVIRUS VECTOR; CD1 ANTIGEN; CD4 ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 4; STAT4 PROTEIN; STAT6 PROTEIN; TYROSINASE RELATED PROTEIN 2; CANCER VACCINE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITF PROTEIN, MOUSE; STAT4 PROTEIN, MOUSE; STAT6 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE DIFFERENTIATION; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; GENE DELETION; IMMUNOPROPHYLAXIS; MELANOMA; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T CELL DEPLETION; TH0 CELL; TUMOR REJECTION; VITILIGO; ANIMAL; BLOOD; C57BL MOUSE; CELL DIFFERENTIATION; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOPHENOTYPING; MOUSE MUTANT; TUMOR CELL LINE;

ANIMALS; AUTOIMMUNITY; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; IMMUNOPHENOTYPING; INTERFERON-GAMMA; INTERLEUKIN-4; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; STAT4 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR;

EID: 67649966551     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200839152     Document Type: Article

References (34)

1. Lane, C., Leitch, J., Tan, X., Hadjati, J., Bramson, J. L. and Wan, Y., Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res. 2004. 64: 1509-1514.
2. Gilboa, E., The risk of autoimmunity associated with tumor immunotherapy. Nat. Immunol. 2001. 2: 789-792.
3. Overwijk, W.W., Lee, D. S., Surman, D. R., Irvine, K. R., Touloukian, C. E., Chan, C. C., Carroll, M. W. et al., Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes. Proc. Natl. Acad. Sci. USA 1999. 96: 2982-2987.
4. Bowne, W. B., Srinivasan, R., Wolchok, J. D., Hawkins, W. G., Blachere, N. E., Dyall, R., Lewis, J. J. and Houghton, A. N., Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 1999. 190: 1717-1722.
5. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D. and Levitsky, H., The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 1998. 188: 2357-2368.
6. Perez-Diez, A., Joncker, N. T., Choi, K., Chan,W. F., Anderson, C. C., Lantz, O. and Matzinger, P., CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007. 109: 5346-5354.
7. Mumberg, D., Monach, P. A., Wanderling, S., Philip, M., Toledano, A. Y., Schreiber, R. D. and Schreiber, H., CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. USA 1999. 96: 8633-8638.
8. + T cells against NY-ESO-1. N. Engl. J. Med. 2008. 358: 2698-2703.
9. Leitch, J., Fraser, K., Lane, C., Putzu, K., Adema, G. J., Zhang, Q. J., Jefferies, W. A. et al., CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine. J. Immunol. 2004. 172: 5200-5205.
10. Mattes, J., Hulett, M., Xie, W., Hogan, S., Rothenberg, M. E., Foster, P. and Parish, C., Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: An eotaxin and STAT6-dependent process. J. Exp. Med. 2003. 197: 387-393.
11. Volpert, O. V., Fong, T., Koch, A. E., Peterson, J. D., Waltenbaugh, C., Tepper, R. I. and Bouck, N. P., Inhibition of angiogenesis by interleukin 4. J. Exp. Med. 1998. 188: 1039-1046.
12. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000. 12: 677-686.
13. Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M. et al., Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008. 112: 362-373.
14. Miner, K. T. and Croft, M., Generation, persistence, and modulation of Th0 effector cells: Role of autocrine IL-4 and IFN-gamma. J. Immunol. 1998. 160: 5280-5287.
15. + T cells produce large amounts of IL-4 and IFN-gamma upon activation by anti-CD3 or CD1. J. Immunol. 1997. 159: 2240-2249.
16. Sherman, M. A., The role of STAT6 in mast cell IL-4 production. Immunol. Rev. 2001. 179: 48-56.
17. Kaplan, M. H., Sun, Y. L., Hoey, T. and Grusby, M. J., Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996. 382: 174-177.
18. Shimoda, K., van Deursen, J., Sangster, M. Y., Sarawar, S. R., Carson, R. T., Tripp, R. A., Chu, C. et al., Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996. 380: 630-633.
19. Goriely, S., Neurath, M. F. and Goldman, M., How microorganisms tip the balance between interleukin-12 family members. Nat. Rev. Immunol. 2008. 8: 81-86.
20. Bettelli, E., Korn, T., Oukka, M. and Kuchroo, V. K., Induction and effector functions of T(H)17 cells. Nature 2008. 453: 1051-1057.
21. Chattopadhyay, P. K., Yu, J. and Roederer, M., Live-cell assay to detect antigen-specific CD4+T-cell responses by CD154 expression. Nat. Protoc. 2006. 1: 1-6.
22. Chitnis, T., Najafian, N., Benou, C., Salama, A. D., Grusby, M. J., Sayegh, M. H. and Khoury, S. J., Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J. Clin. Invest. 2001. 108: 739-747.
23. + T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity 1999. 11: 463-472.
24. Stockinger, B. and Veldhoen, M., Differentiation and function of Th17 T cells. Curr. Opin. Immunol. 2007. 19: 281-286.
25. Mathur, A. N., Chang, H. C., Zisoulis, D. G., Stritesky, G. L., Yu, Q., O'Malley, J. T., Kapur, R. et al., Stat3 and Stat4 direct development of IL-17-secreting Th cells. J. Immunol. 2007. 178: 4901-4907.
26. Kaplan, M. H., Wurster, A. L. and Grusby, M. J., A signal transducer and activator of transcription (Stat)4-independent pathway for the development of T helper type 1 cells. J. Exp. Med. 1998. 188: 1191-1196.
27. Chi, H., Lu, B., Takekawa, M., Davis, R. J. and Flavell, R. A., GADD45beta/GADD45gamma and MEKK4 comprise a genetic pathway mediating STAT4-independent IFNgamma production in T cells. EMBO J. 2004. 23: 1576-1586.
28. Cai, G., Radzanowski, T., Villegas, E. N., Kastelein, R. and Hunter, C. A., Identification of STAT4-dependent and independent mechanisms of resistance to Toxoplasma gondii. J. Immunol. 2000. 165: 2619-2627.
29. Boyton, R. J., Davies, S., Marden, C., Fantino, C., Reynolds, C., Portugal, K., Dewchand, H. and Altmann, D. M., Stat4-null non-obese diabetic mice: Protection from diabetes and experimental allergic encephalomyelitis, but with concomitant epitope spread. Int. Immunol. 2005. 17: 1157-1165.
30. + T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann. Surg. Oncol. 2004. 11: 892-899.
31. +Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: A tumor antigen translated in an alternative open reading frame. J. Immunol. 2003. 170: 1490-1497.
32. Mathew, A., MacLean, J. A., DeHaan, E., Tager, A. M., Green, F. H. and Luster, A. D., Signal transducer and activator of transcription 6 controls chemokine production and T helper cell type 2 cell trafficking in allergic pulmonary inflammation. J. Exp. Med. 2001. 193: 1087-1096.
33. Hoshino, A., Tsuji, T., Matsuzaki, J., Jinushi, T., Ashino, S., Teramura, T., Chamoto, K. et al., STAT6-mediated signaling in Th2-dependent allergic asthma: Critical role for the development of eosinophilia, airway hyperresponsiveness and mucus hypersecretion, distinct from its role in Th2 differentiation. Int. Immunol. 2004. 16: 1497-1505.
34. + T-cell helper epitope. Cancer Res. 2007. 67: 6459-6467.